Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$30,000.00
Jul 26, 2025
For-profit organization
Youth: Support for Automation in Therapy Services
1032723
Automation of repetitive tasks as well as the removal of manual monitoring within the TinyEYE digital therapy application.
$3,318.00
Jul 23, 2025
Not-for-profit organization or charity
Welcome Project Workshops and Activities
GC-3150
This grant supports the Power To Be Society’s development and delivery of Welcome Project training and ongoing collaboration in Learn-to Camp workshops and activities.
$75,000.00
Jul 17, 2025
Academia
Machine-learning algorithms for integrating HDT bed rest data and measuring the deconditioning of physiological systems
25HLSDM2
We will apply machine-learning algorithms to integrated ESA data and gene expression data collected from the same participants by our Team.
$75,000.00
Jul 15, 2025
For-profit organization
Development of RNA therapies for therapeutic modulation of expression
1033096
Scalable platform development for programmable genetic medicines, focused on high-throughput screening and functional validation in engineered cell models. The project enables rapid iteration and optimization of therapeutic candidates for severe neurological and metabolic diseases.
$250,000.00
Jul 2, 2025
For-profit organization
Preclinical development of a combination therapy for the treatment of Hirschsprung disease in newborns
1033406
The project advances preclinical development of the first non-surgical treatment for Hirschsprung disease, a rare congenital disorder that causes severe gastrointestinal issues and risk of sepsis in affected newborns.
$88,000.00
Jul 1, 2025
Not-for-profit organization or charity
Proof of Concept of DNA-Free Genome-Editing System in Chickpea: A Feasibility Study
1031310
The Project will be conducted over 12 months, focusing on the selection of target genes, design and synthesis of guide RNAs, and optimization of transformation protocols.
$200,057.00
Jul 1, 2025
Academia
Innovative Strategies for Non-Viral Generation of iPSC-Derived CAR-T Therapies
1031592
The NRC has created human amniotic fluid-derived iPSCs (HAF-iPSCs) to produce functional T cells for adoptive therapies. This Project aims to validate and optimize the differentiation of HAF-iPSCs into CD4+ and CD8+ T cells, evaluating their performance against established iPSC lines.
$30,000.00
Jul 1, 2025
For-profit organization
Development of Novel EGFR Inhibitors as Cancer Therapeutics
1032219
Aberrant EGFR signaling is a driver mutation in many tumors, making it an ideal and validated target for cancer therapy. Despite many pharmaceutical companies actively advancing EGFR inhibitors, drug resistance and severe side effects remain unsolved challenges that need to be addressed.
$50,400.00
Jul 1, 2025
For-profit organization
Development of Novel Quinazoline-Based EGFR Inhibitors as Cancer Therapeutics
1032220
Aberrant EGFR signaling is a driver mutation in many tumors, making it an ideal and validated target for cancer therapy. Despite many pharmaceutical companies actively advancing EGFR inhibitors, drug resistance and severe side effects remain unsolved challenges that need to be addressed.
$36,000.00
Jul 1, 2025
For-profit organization
Advancement of a Hypoxia-Activated Reagent for Detection and Mapping of Hypoxia in Cells and Tumors
1032297
Firm proposes commercial advancement of one of the lead candidates that offers time & cost-effective precision imaging and quantification of tumor hypoxia, which will help determine an effective therapy plan for patients and offer socioeconomic benefits.